A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.

Front Oncol · 2021 · PMC8517073 · PMID 34660287

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significancep = 0.058so close (0.05 < p ≤ 0.1)

However, patients who received EGFR-TKI plus crizotinib had a trend of longer OS, with a median OS of 10.0 months but did not reach statistical significance [ vs . crizotinib p = 0.058; HR = 0.65, 95% CI (0.48, 1.92), adjp = 0.17; vs . chemotherapy p = 0.095; HR = 0.59, 95% CI (0.35, 1.8), adjp = 0.20; Figure 2C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.